Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Beacon Therapeutics said its investigational gene therapy for X-linked retinitis pigmentosa (XLRP) met its primary endpoint in a pivotal trial, with patients showing improved visual acuity. XLRP is a rare inherited condition that causes progressive vision loss and can lead to blindness.
The company framed the result as a step toward regulatory submission, with an FDA approval request now on the horizon. According to the report, the outcome is especially notable because larger pharmaceutical companies have had difficulty finding success in this particular form of vision loss, leaving room for a smaller biotech to lead.
The trial data were described as positive, though the source did not provide detailed safety or durability figures. Beacon now moves forward with plans to seek regulatory approval for the therapy.
Sources · 2
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.
Novo Nordisk seeks to reassure investors with new drug pipeline
At a capital markets day, Novo's CEO acknowledged investor doubts and outlined plans to compete with Eli Lilly and launch several multibillion-dollar products.